Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron.
Berman SM, Chang L, Suyenobu B, Derbyshire SW, Stains J, Fitzgerald L, Mandelkern M, Hamm L, Vogt B, Naliboff BD, Mayer EA.
Berman SM, et al. Among authors: mayer ea.
Gastroenterology. 2002 Oct;123(4):969-77. doi: 10.1053/gast.2002.35990.
Gastroenterology. 2002.
PMID: 12360456
Clinical Trial.